middle.news
Neurizon CEO Resigns: Who Will Lead Next in ALS Drug Race?
8:34am on Monday 16th of March, 2026 AEDT
•
Biotechnology
Read Story
Neurizon CEO Resigns: Who Will Lead Next in ALS Drug Race?
8:34am on Monday 16th of March, 2026 AEDT
Key Points
Dr Michael Thurn resigns as CEO, remains non-executive director until July 2026
Interim Executive Chair Sergio Duchini appointed to maintain leadership continuity
Global CEO search underway with Coulter Partners engaged
Dr Thurn credited with advancing lead drug candidate NUZ-001 through clinical phases
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE